Insider Selling: iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares of Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $97.66, for a total value of $488,300.00. Following the completion of the sale, the chief executive officer owned 2,282,500 shares in the company, valued at $222,908,950. The trade was a 0.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

iRadimed Trading Up 0.0%

iRadimed stock traded up $0.03 during mid-day trading on Tuesday, hitting $97.77. The company had a trading volume of 40,336 shares, compared to its average volume of 52,667. iRadimed Corporation has a 12 month low of $47.48 and a 12 month high of $98.53. The company has a market capitalization of $1.24 billion, a PE ratio of 59.25 and a beta of 1.06. The stock’s 50 day moving average price is $89.18 and its two-hundred day moving average price is $74.61.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities research analysts anticipate that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Dividend Announcement

The business also recently declared a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is presently 41.21%.

Institutional Investors Weigh In On iRadimed

Several institutional investors and hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC lifted its holdings in shares of iRadimed by 408.8% in the 2nd quarter. SG Americas Securities LLC now owns 36,516 shares of the medical equipment provider’s stock worth $2,183,000 after acquiring an additional 29,339 shares during the last quarter. Nuveen LLC purchased a new stake in iRadimed in the 1st quarter worth about $1,418,000. Johnson Investment Counsel Inc. bought a new stake in iRadimed in the second quarter worth about $1,534,000. Algert Global LLC boosted its position in shares of iRadimed by 87.5% during the third quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock valued at $3,615,000 after buying an additional 23,710 shares during the period. Finally, UBS Group AG grew its stake in shares of iRadimed by 389.9% during the third quarter. UBS Group AG now owns 25,433 shares of the medical equipment provider’s stock valued at $1,810,000 after buying an additional 20,242 shares during the last quarter. Institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the topic of several research reports. Wall Street Zen cut shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Zacks Research upgraded iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Lake Street Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday. Finally, Roth Capital set a $90.00 price target on iRadimed in a report on Friday, October 31st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, iRadimed currently has an average rating of “Moderate Buy” and a consensus price target of $87.33.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.